Patent reform bill passes Senate
- 28 February, 2012 14:06
- Comments 1
Australia’s patent laws are facing their most significant revision in over two decades after the Raising the Bar bill passed the Senate during a sitting last night.
Following a debate on the current revision of the bill, it was passed by the Senate and passed over for reading in the House of Representatives.
The bill recommends several key revisions to the existing patent laws as established in the Patents Act 1990, including a research exemption that allows scientists to use intellectual property protected by patents for continued research.
Coalition Senators spoke in support of the bill, although they suggested it serve as a foundation for further reforms to intellectual property laws in the future.
Senator Bill Heffernan, who also co-introduced a bill to ban gene patents, also spoke in support of the current bill, although he stressed his concern over the distinction between discovery and invention.
“The problem we have in the patent world – and Australia is a soft entry point for patents globally – is that we have included in the patents, which have now been challenged in Australian and American courts, the discoverable material,” he said.
Senator Nick Xenophon, who has also agitated against gene patents, also gave reserved support for the bill.
“This piece of legislation is not unwelcome,” he said. “But I believe it ought to have gone much further. I would like to think that this is the beginning of further reforms.”
The bill was introduced to the Senate on 22 June last year, and raises the threshold to be granted a patent as well as offers a research exemption and updates other elements of the patent system.
Senator Kim Carr, Minister for Manufacturing and Minister for Defence Materiel, stressed that the bill will significantly improve patent law in Australia in a number of ways.
“This bill when enacted will speed up the process of resolving patent and trademark applications,” he said. “It will provide applications and the public with much better opportunities to ensure that they have the protections of patent law.
“The law helps IP professionals to assist those who seek to take advantage of the patent system. It makes it easier for them to secure a patent, but not for trivial things.
“It provides a much stronger quality of advice by making it easier to ensure that we can secure the necessary legal protections for people. It protects people from imitations and fakes. It provides better border protection systems and stronger sanctions against counterfeits.
“Finally, the bill simplifies the more technical aspects of the current IP system so that innovators can spend less time prosecuting applications and more time innovating.
“That is why the bill is so named: raising the bar. It raises the quality of the innovation system to raise the quality of innovation and to benefit all Australians. That is why I argue we ought to support this bill and we ought to give it rapid passage.”
AusBiotech, which has supported the patent amendments, particularly the research amendment while maintaining strong protection for intellectual property, welcomed the passing the bill through the Senate.
“More than two years of consultation and deliberation that has resulted in the passing of the ‘Raising the Bar’ bill, will strengthen Australia’s IP management system,” said Dr Anna Lavelle, CEO of AusBiotech.
“The bill answers the stated community and concerns over patient and research access, while ensuring a patent system that will encourage development of new biotechnologies.
“We believe there is no downside to the Bill and members of Parliament ought to feel confident supporting legislation that is guaranteed to make an improvement.”
The bill will now be read in the House of Representatives.
-
UniQuest brokers international biofuel partnership
-
Apollo develops needle-free topical vaccine
-
Study reveals link between tea and rheumatoid arthritis
-
Halcygen (ASX:HGN) to expand board following departure of director and COO
-
AstraZeneca invests in Victoria's NeuProtect
-
Introduction to Statistics for Forensic Scientists
-
Molecular Forensics
-
The Scientific American a Day in the Life of Your Brain
-
Molecular & Cell Biology for Dummies
-
Fluorescence Applications in Biotechnology and Life Sciences
-
Proteins - Structure and Function
-
An Introduction to Molecular Biotechnology - Molecular Fundamentals, Methods and Applications in Modern Biotechnology
-
Writing Scientific Research Articles - Strategy and Steps
-
Dictionary of DNA and Genome Technology 2E


Comments
plenty of downside
"no downside". How about the fact that many biotechs that used to rely on licencing fees are now unable to conduct research themselves due to lack of income. Researchers worldwide stopped paying licence fees years ago since the law was passed in the US seven years ago. Biotechs will all be going the way of the dodo anyway if the Australian Government don't wake up to the fact that the industry is dying, and the most talented scientist have to seek employment abroad if they want to actually advancer their careers. I'm all for encouraging research, but here in Australia the funding is about 1/50th of what it is in the US per capita, and they are broke. Sure, BigPharma are happy because all they have to do is stop collaborating with the biotechs that do all the innovating because they can just let them go bankrupt and end up buying all the IP in a fire sale anyway. 15 years for a drug to get to market is too long for these biotechs to wait until someone starts paying licence fees or royalties. BigPharma will just wait for the patents to expire anyway before commercialisation so they end up with 100% of the profits. I'm all for encouraging research, but once Phase I study begin, licence fees should be payable, otherwise BigPharma just end up with an even greater stranglehold over the industry, charging like wounded bulls in the process, leaving the majority unable to afford life-saving drugs anyway.
Post new comment